New phosphodiesterase inhibitors in the treatment of erectile dysfunction

Authors: Paul CB Anderson; Lyndon Gommersall; Dickon Hayne; Manit Arya; Hitendra RH Patel

Source: Expert Opinion on Pharmacotherapy, Volume 5, Number 11, 1 November 2004 , pp. 2241-2249(9)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., intracavernosal injection). Whilst sildenafil remains the market leader for ED treatment, it does have some shortcomings: its clinical efficacy is diminished in ‘difficult to treat’ patient groups, such as diabetics, side effects, such as blue-tinged vision and headache, and the need to time the ingestion of sildenafil to 1 h prior to expected time of sexual intercourse. Recently, newer phosphodiesterase inhibitors (‘sons of viagra’) have become available, and potentially to improve upon, what has become regarded as the gold standard for ED treatment. This review article discusses the differences between vardenafil, tadalafil and sildenafil, in order to allow the clinician to make an informed decision as to which phosphodiesterase inhibitor to prescribe when dealing with the ever expanding number of patients seeking help for ED.

Keywords: Erectile dysfunction; phosphodiesterase-5 inhibitors; sildenafil; tadalafil; vardenafil

Document Type: Review article

DOI: http://dx.doi.org/10.1517/14656566.5.11.2241

Publication date: 2004-11-01

More about this publication?